SCHEMBL20788846

SCHEMBL20788846

CCCCCCCCCCCCCCOC(C(O)CO)C(O)(CCCCCCCCCCCCCC)C(O)CO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.38
CNR1 P21554 5/20 0.36
CNR2 P34972 5/20 0.36
ALDH1A1 P00352 1/20 0.34
PLA2G2C Q5R387 1/20 0.34
MGAM O43451 2/20 0.33
DNM1 Q05193 1/20 0.33
CYP2D6 P10635 2/20 0.33
SPHK1 Q9NYA1 2/20 0.33
GMNN O75496 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
THPO P40225 1/20 0.33
MTOR P42345 1/20 0.33
BLM P54132 1/20 0.33
KDM4E B2RXH2 1/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30203353 1.00 USP2 (0.38) USP2CNR1CNR2ALDH1A1PLA2G2C
SCHEMBL20788857 1.00 USP2 (0.38) USP2CNR1CNR2ALDH1A1PLA2G2C
SCHEMBL20788837 1.00 USP2 (0.38) USP2CNR1CNR2ALDH1A1PLA2G2C
SCHEMBL20788830 1.00 USP2 (0.38) USP2CNR1CNR2ALDH1A1PLA2G2C
SCHEMBL20788839 1.00 USP2 (0.38) USP2CNR1CNR2ALDH1A1PLA2G2C
SCHEMBL20788854 1.00 USP2 (0.38) USP2CNR1CNR2ALDH1A1PLA2G2C
SCHEMBL20788814 1.00 USP2 (0.38) USP2CNR1CNR2ALDH1A1PLA2G2C
SCHEMBL20788843 1.00 USP2 (0.38) USP2CNR1CNR2ALDH1A1PLA2G2C
SCHEMBL20788851 1.00 USP2 (0.38) USP2CNR1CNR2ALDH1A1PLA2G2C
SCHEMBL30203416 1.00 USP2 (0.38) USP2CNR1CNR2ALDH1A1PLA2G2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10889609-B2 Mannitol-based amphipathic compound and use thereof INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) 2021-01-12 US disclosed
US-20190077822-A1 NOVEL MANNITOL-BASED AMPHIPATHIC COMPOUND AND USE THEREOF INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) 2019-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077822-A1 NOVEL MANNITOL-BASED AMPHIPATHIC COMPOUND AND USE THEREOF MIA3, MAN1B1, MPI USP2 3906/4885CNR1 2577/4885CNR2 3239/4885
US-10889609-B2 Mannitol-based amphipathic compound and use thereof MAN1B1, MPI, MIA3 USP2 4153/4885CNR1 2356/4885CNR2 2939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.